Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand starting March 9, 2021, at 7:00 am ET via the Neoleukin investors section of their website. Neoleukin specializes in de novo protein therapeutics, focusing on advanced immunotherapies for cancer and autoimmune diseases. Their lead candidate is NL-201, an agonist designed to enhance tolerability and efficacy.
Neoleukin Therapeutics, a biopharmaceutical company listed on NASDAQ under the ticker NLTX, announced that CEO Jonathan Drachman will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on March 12, 2021, at 3 p.m. ET. A live audio webcast will be available on the company's investor website, along with an archived replay for 30 days post-event. Neoleukin focuses on creating next-generation immunotherapies using de novo protein design technology, with its lead candidate, NL-201, targeting improved efficacy and tolerability.
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced on January 7, 2021, that it received a clinical hold letter from the FDA regarding its IND application for the Phase 1 study of NL-201, its immunotherapeutic candidate. The FDA's hold requires Neoleukin to develop a new assay for accurately measuring protein dosage and address additional non-hold related requests. CEO Jonathan Drachman expressed the company's commitment to respond swiftly and work closely with the FDA to resolve these issues.
NL-201 is designed to enhance cancer-fighting CD8 T cells and NK cells.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 4:30 p.m. ET. The presentation will include a live audio webcast and a subsequent Q&A session, accessible via the Neoleukin investor website. Neoleukin focuses on developing next-generation immunotherapies using de novo protein design technology, with its leading candidate, NL-201, aimed at enhancing the treatment of cancer and autoimmune diseases.
Neoleukin Therapeutics (NASDAQ:NLTX) has submitted an Investigational New Drug (IND) Application to the U.S. FDA for its lead immunotherapeutic candidate, NL-201, marking a significant milestone for the company. NL-201 is designed to mimic natural cytokines IL-2 and IL-15. The Phase 1 clinical trial, which will include up to 120 patients with relapsed or refractory solid tumors, aims to evaluate safety and anti-tumor activity. The study will be conducted in North America and Australia, with patient enrollment expected to commence soon.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded session will be available starting at 10 a.m. ET on November 23, 2020, via the investors section of Neoleukin's website. Neoleukin focuses on developing next-generation immunotherapies, leveraging innovative computational methods for protein design. Their lead candidate, NL-201, combines IL-2 and IL-15 agonists aimed at enhancing therapeutic benefits.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. The event will be available via live audio webcast on the Neoleukin website, with an archived replay accessible for 30 days post-event. Neoleukin specializes in developing immunotherapies for cancer and autoimmune diseases using advanced computational methods to design innovative protein therapeutics. Their lead candidate, NL-201, aims to enhance efficacy by targeting specific receptors.
Summary not available.
Neoleukin Therapeutics (NASDAQ: NLTX) reported financial results for Q3 2020, ending with $201.2 million in cash, up from $143.1 million at the end of 2019. The company is on track to submit an IND for NL-201, its lead immunotherapy candidate, by year-end 2020, and has submitted a CTN application in Australia. R&D expenses rose to $6.2 million, reflecting ongoing development, while general and administrative expenses decreased to $3.9 million. A gain of $7.8 million from the sale of Aquinox Canada contributed to a reduced net loss of $2.2 million, down from $59.1 million the prior year.
Neoleukin Therapeutics (NASDAQ:NLTX) announced a significant breakthrough in COVID-19 treatment with their de novo protein, NL-CVX1. Published in Science, the research demonstrates that NL-CVX1 effectively prevents SARS-CoV-2 infection in hamsters, maintaining survival after exposure to a lethal virus dose. This protein mimics the natural receptor for SARS-CoV-2, showing promise against viral mutations. The company is evaluating advancing this promising molecule to clinical trials in humans, showcasing their innovative protein design technology.